Bone Resorption Inhibitors
Zoledronic Acid
C.A.S.: [904894-54-8]
Process Patent AR P050103131 filed July, 2005 and WO 2007/16982. Drug Master File submitted to the FDA, European Regulatory Authorities and K-FDA (Korea). Manufacturing Process Audited and Approved by FDA (2011)
In house specifications. For further information contact us.
Sodium Ibandronate
C.A.S.: [138926-19-9]
Drug Master File submitted to the FDA, European Regulatory Authorities and K-FDA (Korea). Manufacturing Process Audited and Approved by K-FDA (2011). In house specifications. For further information contact us.
Sodium Alendronate
C.A.S.: [121268-17-5]
Drug Master File submitted to the FDA, European Regulatory Authorities and K-FDA (Korea). Specifications according to Ph. Eur. For further information contact us.
Pamidronic Acid

Drug Master File submitted to the FDA, TGA (Australia) and European Regulatory Authorities. Manufacturing Process Audited and Approved by FDA (2001, 2007 and 2011). In house specifications. For further information contact us.
Sodium Pamidronate
C.A.S.: [5724-88-1]
Process Patent AR 218.558 (june 13, 1980) .Specifications according to Ph. Eur.. For further information contact us.
Central Nervous System
Alprazolam
CAS: [28981-97-7]
Short Characteristics: Sedative
Specifications according to Eur. Ph.
For further information contact us.
Desvenlafaxine Succinate
CAS: [386750-22-7]
Short Characteristics: Antidepressant
In-house Specifications.
For further information contact us
Agomelatine
CAS: [138112
-76-2]
Short Characteristics: Antidepressant
In-house Specifications.
For further information contact us.
Zaleplon

C.A.S.: [151319-34-5]
Process Patent AR P000106596 (Files December, 2000) and US 6.476.223 B2 (Novembre 5, 2002).
Drug Master File submitted to the FDA.
Manufacturing Process Audited and Approved by FDA (2007 and 2011)
In-house specifications.
For further information contact us.
Zolpidem Tartrate
C.A.S.: [99294-93-6]
Process Patent AR 255060.
Drug Master File submitted to the FDA and European Regulatory Authorities Manufacturing
Process Audited and Approved by Afssaps (France, 2007)
Specifications according to Ph. Eur.
For further information contact us.
Hormones
Norelgestromin 18-Methyl-norethindrone oxime

CAS: [53016-31-2
Short Characteristics: Progestogen
Process Patent AR P 03 01 02267 (filed July,2003) and US 2004/0266741 A1
Drug Master File submitted to the FDA
In-house Specifications.
For further information contact us.
Nomegestrol Acetate

Short Characteristics: Progestogen
Specifications according to Eur. Ph.
For further information contact us.
Norgestimate (RO – CEP 2010-012-Rev 00)

C.A.S. R.N.: [35189-28-7]
Drug Master File submitted to the FDA
Manufacturing Process Audited and Approved by FDA (2007 and 2011)
Specifications according to USP and Ph. Eur.
For further information contact us.
Antigout
Febuxostat
CAS: [144060-53-7]
Process Patent (USA) Application Number 61/39210 (October 14, 2010)
In-house Specifications.
For further information contact us.
Prostate disorders
Dutasteride
CAS: [164656-23-9]
Process Patent WO 2009/083258 A2 (Filed January, 2008).
Drug Master File submitted to the FDA.
In-house Specifications.
For further information contact us.
Haematological
Plerixafor
CAS: [155148-31-5]
PIn-house Specifications.
For further information contact us
Anorexic
Mazindol
CAS: [22232-71-9]
Short Characteristics: Anorexic
Specifications according to USP.
For further information contact us.